To watch more from Medscape for free visit here: www.staging.medscape.com/view...
I'm Dr Maurie Markman from Cancer Treatment Centers of America. I wanted to talk briefly about a very important paper that recently appeared in the Annals of Oncology. The paper is titled "The Impact of Olaparib Dose Reduction and Treatment Interruption on Treatment Outcome in the SOLO2/ENGOT-ov21 Platinum-Sensitive Recurrent Ovarian Cancer."
The particular focus of this paper is on what happens if a patient has adverse events during the first couple of months of olaparib therapy and is not able to receive all the drug or all the drug on time. Does this have a negative impact on clinical outcome?